Return to Today's science sparks archives

2021-05-03

Fig 1. Burnout versus burnout syndrome. High risk for burnout is classified as reaching threshold levels of either emotional exhaustion and/or depersonalization

Fig 1. Burnout versus burnout syndrome. High risk for burnout is classified as reaching threshold levels of either emotional exhaustion and/or depersonalization
  • Afonso AM, Cadwell JB, Staffa SJ, Zurakowski D, Vinson AE

  • Anesthesiology. 2021 May 1;134(5):683-696. doi: 10.1097/ALN.0000000000003722.

2021-05-04

Graphical abstract.

Graphical abstract.
  • Szanto CL, Cornel AM, Tamminga SM, Delemarre EM, de Koning CCH, van den Beemt DAMH, Dunnebach E, Tas ML, Dierselhuis MP, Tytgat LGAM, van Noesel MM, Kraal KCJM, Boelens JJ, Huitema ADR, Nierkens S

  • Cancers (Basel). 2021 Apr 26;13(9). pii: cancers13092096. doi: 10.3390/cancers13092096.
Open Access button

2021-05-05

Fig 1. KRAS mutation subtypes and baseline pathologic and molecular characteristics.

Fig 1. KRAS mutation subtypes and baseline pathologic and molecular characteristics.
  • Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ

  • Clin Cancer Res. 2021 Apr 15;27(8):2209-2215. doi: 10.1158/1078-0432.CCR-20-4023. Epub 2021 Feb 8.

2021-05-06

Fig. 2: Best RECIST response, PTEN, and broader mutation profiling in patients with PTEN-mutant ER+ MBC treated with capivasertib and fulvestrant.

Fig. 2: Best RECIST response, PTEN, and broader mutation profiling in patients with PTEN-mutant ER+ MBC treated with capivasertib and fulvestrant.
  • Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S

  • NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7.
Open Access button

2021-05-07

Figure 2. Subgroup analysis of 90-day mortality and survival after ICU admission

Figure 2. Subgroup analysis of 90-day mortality and survival after ICU admission
  • Azoulay E, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Boll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S

  • Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0.

2021-05-10

Figure 1. SNPs in high LD of the index SNP (rs35418111) in Asians (rs8134832, rs57385578, rs8126917, and rs2078203) and Europeans (rs57385578) were prioritized using HaploReg v4.1 annotation.

Figure 1. SNPs in high LD of the index SNP (rs35418111) in Asians (rs8134832, rs57385578, rs8126917, and rs2078203) and Europeans (rs57385578) were prioritized using HaploReg v4.1 annotation.
  • Shidal C, Shu X, Wu J, Wang J, Huang S, Long J, Bauer JA, Ping J, Guo X, Zheng W, Shu XO, Cai Q

  • Cancers (Basel). 2021 Apr 23;13(9). pii: cancers13092037. doi: 10.3390/cancers13092037.
Open Access button

2021-05-11

QSER1 safeguards DNA methylation valleys from de novo methylation.

QSER1 safeguards DNA methylation valleys from de novo methylation.
  • Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S, Glezer A, Liu C, Rivas M, Kumar R, Lan Y, Torregroza I, He C, Sidoli S, Evans T, Elemento O, Huangfu D

  • Science. 2021 Apr 9;372(6538). pii: 372/6538/eabd0875. doi: 10.1126/science.abd0875.

2021-05-12

Fig. 2: Common primary cancers metastasizing to the liver.

Fig. 2: Common primary cancers metastasizing to the liver.
  • Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibanes E, Pawlik TM

  • Nat Rev Dis Primers. 2021 Apr 15;7(1):27. doi: 10.1038/s41572-021-00261-6.

2021-05-13

Figure 1 Dose‐normalized plasma galunisertib concentrations at steady state (following treatment on day 14) with monotherapy (Part A) and combination with ramucirumab (Part D).

Figure 1 Dose‐normalized plasma galunisertib concentrations at steady state (following treatment on day 14) with monotherapy (Part A) and combination with ramucirumab (Part D).
  • Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK

  • Cancer Med. 2021 Apr 2. doi: 10.1002/cam4.3880.
Open Access button

2021-05-14

Fig 1. Waterfall plots of best response to entrectinib in patients with ROS proto-oncogene 1 (ROS1) fusion–positive lung cancers, shown as the maximum percent improvement in the sum of longest diameters of identified target lesions compared with baseline, as assessed by BICR.

Fig 1. Waterfall plots of best response to entrectinib in patients with ROS proto-oncogene 1 (ROS1) fusion–positive lung cancers, shown as the maximum percent improvement in the sum of longest diameters of identified target lesions compared with baseline, as assessed by BICR.
  • Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F

  • J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.

2021-05-17

Fig 2. Mutational signature landscape in first responders and recovery workers exposed to the WTC disaster.

Fig 2. Mutational signature landscape in first responders and recovery workers exposed to the WTC disaster.
  • Maura F, Diamond B, Maclachlan KH, Derkach A, Yellapantula VD, Rustad EH, Hultcrantz M, Shah UA, Hong J, Landau HJ, Iacobuzio-Donahue CA, Papaemmanuil E, Irby S, Crowley L, Crane M, Webber MP, Goldfarb DG, Zeig-Owens R, Giricz O, Verma A, Prezant DJ, Dogan A, Shah SP, Zhang Y, Landgren O

  • Clin Cancer Res. 2021 Apr 1;27(7):2111-2118. doi: 10.1158/1078-0432.CCR-20-2245. Epub 2021 Jan 27.

2021-05-18

Fig 1. Terminal elongation-defective phenotypes for TS-EL mutants after L4 and late upshifts.

Fig 1. Terminal elongation-defective phenotypes for TS-EL mutants after L4 and late upshifts.
  • Jud MC, Lowry J, Padilla T, Clifford E, Yang Y, Fennell F, Miller AK, Hamill D, Harvey AM, Avila-Zavala M, Shao H, Nguyen Tran N, Bao Z, Bowerman B

  • G3 (Bethesda). 2021 Apr 15;11(4). pii: 6169531. doi: 10.1093/g3journal/jkab026.
Open Access button

2021-05-19

Figure 1: Mouse NK cell development and maturation.

Figure 1: Mouse NK cell development and maturation.
  • Mujal AM, Delconte RB, Sun JC

  • Annu Rev Immunol. 2021 Apr 26;39:417-447. doi: 10.1146/annurev-immunol-101819-074948.

2021-05-20

Fig. 1 RIF1 controls RT by reducing cell-to-cell variation in replication timing.

Fig. 1 RIF1 controls RT by reducing cell-to-cell variation in replication timing.
  • Klein KN, Zhao PA, Lyu X, Sasaki T, Bartlett DA, Singh AM, Tasan I, Zhang M, Watts LP, Hiraga SI, Natsume T, Zhou X, Baslan T, Leung D, Kanemaki MT, Donaldson AD, Zhao H, Dalton S, Corces VG, Gilbert DM

  • Science. 2021 Apr 23;372(6540):371-378. doi: 10.1126/science.aba5545. Epub 2021 Apr 22.

2021-05-21

Figure 3: Germline and somatic causes of neurodegeneration.

Figure 3: Germline and somatic causes of neurodegeneration.
  • Cox N, Pokrovskii M, Vicario R, Geissmann F

  • Annu Rev Immunol. 2021 Apr 26;39:313-344. doi: 10.1146/annurev-immunol-093019-111748.

2021-05-24

Fig 2. Reflectance confocal microscopy features seen across time in the study patients.

Fig 2. Reflectance confocal microscopy features seen across time in the study patients.
  • Navarrete-Dechent C, Cordova M, Liopyris K, Aleissa S, Rajadhyaksha M, Cohen G, Marghoob AA, Rossi AM, Barker CA

  • J Am Acad Dermatol. 2021 Jun;84(6):1575-1584. doi: 10.1016/j.jaad.2020.07.130. Epub 2020 Aug 20.

2021-05-25

Figure 1 Transcriptomic similarities across carcinomas with mucinous differentiation from different cancer types.

Figure 1 Transcriptomic similarities across carcinomas with mucinous differentiation from different cancer types.
  • Nguyen B, Sanchez-Vega F, Fong CJ, Chatila WK, Boroujeni AM, Pareja F, Weigelt B, Sotiriou C, Larsimont D, Reis-Filho JS, Desmedt C, Schultz N

  • Sci Rep. 2021 May 4;11(1):9478. doi: 10.1038/s41598-021-89099-2.
Open Access button

2021-05-26

Fig. 3: Repertoire of non-synonymous somatic mutations identified in metaplastic breast cancers.

Fig. 3: Repertoire of non-synonymous somatic mutations identified in metaplastic breast cancers.
  • da Silva EM, Selenica P, Vahdatinia M, Pareja F, Da Cruz Paula A, Ferrando L, Gazzo AM, Dopeso H, Ross DS, Bakhteri A, Riaz N, Chandarlapaty S, Razavi P, Norton L, Wen HY, Brogi E, Weigelt B, Zhang H, Reis-Filho JS

  • NPJ Breast Cancer. 2021 Apr 16;7(1):43. doi: 10.1038/s41523-021-00250-8.
Open Access button

2021-05-27

Fig. 3. Cryo-EM structure of the Nse5/Nse6 complex.

Fig. 3. Cryo-EM structure of the Nse5/Nse6 complex.
  • Yu Y, Li S, Ser Z, Sanyal T, Choi K, Wan B, Kuang H, Sali A, Kentsis A, Patel DJ, Zhao X

  • Proc Natl Acad Sci U S A. 2021 May 11;118(19). pii: 2026844118. doi: 10.1073/pnas.2026844118.

2021-05-28

Figure 1. Radiation treatment plan with isodose lines for a prescribed dose of 24 Gy in 1 fraction delivered to the L2 and L3 vertebral bodies.

Figure 1. Radiation treatment plan with isodose lines for a prescribed dose of 24 Gy in 1 fraction delivered to the L2 and L3 vertebral bodies.
  • Sarkar R, Schmitt AM, Yamada Y

  • Pract Radiat Oncol. 2021 May-Jun;11(3):e348-e350. doi: 10.1016/j.prro.2021.02.004.

2021-06-01

Graphical Abstract.

Graphical Abstract.
  • Xu K, Yin N, Peng M, Stamatiades EG, Chhangawala S, Shyu A, Li P, Zhang X, Do MH, Capistrano KJ, Chou C, Leslie CS, Li MO

  • Immunity. 2021 May 11;54(5):976-987.e7. doi: 10.1016/j.immuni.2021.04.008.